Tissue Regenix Faces Urgent Funding Crisis as Regenerative Medicine Company Seeks £5M to Avoid Insolvency
核心洞察
Tissue Regenix (搜索), a regenerative medical devices company, faces an urgent funding crisis with substantial creditor backlog and very limited cash balances requiring capital by end of November to continue trading.
The company secured a $500K emergency overdraft from existing lender MidCap (搜索) to make November payroll and remain solvent while pursuing larger funding solutions.
Major shareholders have indicated support for raising approximately £5M through a convertible loan note, subject to shareholder approval, to address immediate needs and restore revenue growth.
Tissue Regenix (搜索) Group plc, a regenerative medical devices company specializing in tissue scaffold technology, is facing a critical funding shortage that threatens its ability to continue operations. The company announced it has an urgent need to raise capital by the end of November 2025, warning that without additional funding, it will not be able to continue trading.
Emergency Measures and Immediate Funding
The company has secured a $500K emergency overdraft from MidCap (搜索), its existing lender, which enabled Tissue Regenix (搜索) to make November payroll and remain solvent. This emergency funding provides temporary relief while the company pursues larger capital solutions to address its substantial creditor backlog and restore revenue growth.
The Senior Leadership Team, led by Executive Chairman Jay LeCoque, continues to clarify both the immediate funding needs and the larger capital sum required to restore the business to growth trajectory. The team has been reviewing previously announced revenue restatements for the financial year ended December 31, 2024, and their impact on H125 adjusted EBITDA.
Shareholder Support and Funding Plans
Major shareholders have provided clear indications of support to raise approximately £5M through a convertible loan note structure. The company remains in active dialogue with these stakeholders regarding both short- and medium-term funding requirements. Any fundraising initiative will require shareholder approval before proceeding.
Tissue Regenix (搜索) expects to provide additional updates and post a circular to shareholders later this week, with further details on the convertible loan note fundraising to follow in due course.
Company Technology and Market Position
Tissue Regenix (搜索) operates as a leading medical device company in regenerative medicine, utilizing its patented decellularisation technology known as dCELL (搜索)®. This proprietary technology removes DNA and other cellular material from animal and human soft tissue, creating an acellular tissue scaffold that avoids rejection by the patient's body and can repair diseased or damaged body structures.
The company's current applications address critical clinical needs across multiple therapeutic areas, including sports medicine, foot and ankle injuries, and wound care. Through its 2017 acquisition of CellRight Technologies (搜索)®, Tissue Regenix (搜索) expanded its portfolio to include human tissue products used in spine, trauma, general orthopaedic, dental, and ophthalmological surgical procedures.
Trading Status and Market Impact
The company's ordinary shares remain under temporary suspension on AIM following the October 22, 2025 announcement regarding financial irregularities. The current funding crisis stems from the discovery of substantial creditor obligations and limited cash reserves during the new Senior Leadership Team's comprehensive review of the business.